Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 2
1998 1
2004 1
2005 2
2006 2
2007 1
2008 3
2009 4
2010 5
2011 3
2012 21
2013 19
2014 38
2015 59
2016 81
2017 87
2018 120
2019 162
2020 196
2021 184
2022 182
2023 147
2024 64

Text availability

Article attribute

Article type

Publication date

Search Results

1,193 results

Results by year

Filters applied: . Clear all
Page 1
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA. Strober B, et al. J Am Acad Dermatol. 2023 Jan;88(1):40-51. doi: 10.1016/j.jaad.2022.08.061. Epub 2022 Sep 14. J Am Acad Dermatol. 2023. PMID: 36115523 Free article. Clinical Trial.
METHODS: POETYK psoriasis second trial (NCT03611751), a 52-week, double-blinded, phase 3 trial, randomized patients 2:1:1 to deucravacitinib 6 mg every day (n = 511), placebo (n = 255), or apremilast 30 mg twice a day (n = 254). RESULTS: At week 16, significantly more deuc …
METHODS: POETYK psoriasis second trial (NCT03611751), a 52-week, double-blinded, phase 3 trial, randomized patients 2:1:1 to deucravacitinib …
Apremilast in dermatology: A review of literature.
Nassim D, Alajmi A, Jfri A, Pehr K. Nassim D, et al. Dermatol Ther. 2020 Nov;33(6):e14261. doi: 10.1111/dth.14261. Epub 2020 Sep 27. Dermatol Ther. 2020. PMID: 32876993 Review.
Apremilast is an orally administered small molecule that specifically inhibits the phosphodiesterase-4 enzyme and modulates the immune system by increasing the levels of intracellular cyclic adenosine monophosphate (cAMP) and inhibiting IL-2 & 8, interferon-gamma and t …
Apremilast is an orally administered small molecule that specifically inhibits the phosphodiesterase-4 enzyme and modulates the immun …
Deucravacitinib in the treatment of psoriasis.
Estevinho T, Lé AM, Torres T. Estevinho T, et al. J Dermatolog Treat. 2023 Dec;34(1):2154122. doi: 10.1080/09546634.2022.2154122. Epub 2022 Dec 13. J Dermatolog Treat. 2023. PMID: 36453809 Free article. Review.
RESULTS: Two phase 3, 52-week trials evaluated deucravacitinib 6 mg against placebo and apremilast - POETYK PSO-1 and PSO-2, enrolling 1688 patients with moderate-to-severe psoriasis. At week 16, over 50% of patients treated with deucravacitinib reached PASI75, significant …
RESULTS: Two phase 3, 52-week trials evaluated deucravacitinib 6 mg against placebo and apremilast - POETYK PSO-1 and PSO-2, enrollin …
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
Stein Gold LF, Bagel J, Tyring SK, Hong HC, Pavlovsky L, Vender R, Pinter A, Reich A, Drogaris L, Wu T, Patel M, Soliman AM, Photowala H, Stakias V, Richter S, Papp KA. Stein Gold LF, et al. Br J Dermatol. 2023 Oct 25;189(5):540-552. doi: 10.1093/bjd/ljad252. Br J Dermatol. 2023. PMID: 37488811 Clinical Trial.
The enrolled patients (randomized 1 : 2) received subcutaneous risankizumab (150 mg at weeks 0 and 4) or oral apremilast (30 mg twice daily). At week 16, all patients treated with apremilast were re-randomized (1 : 1) to risankizumab or apremilast, stratified …
The enrolled patients (randomized 1 : 2) received subcutaneous risankizumab (150 mg at weeks 0 and 4) or oral apremilast (30 mg twice …
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, Hu C, Stevens RM, Day RM, Gordon KB, Korman NJ, Griffiths CE. Papp K, et al. J Am Acad Dermatol. 2015 Jul;73(1):37-49. doi: 10.1016/j.jaad.2015.03.049. J Am Acad Dermatol. 2015. PMID: 26089047 Free article. Clinical Trial.
BACKGROUND: Apremilast works intracellularly to regulate inflammatory mediators. ...CONCLUSIONS: Apremilast was effective in moderate to severe plaque psoriasis....
BACKGROUND: Apremilast works intracellularly to regulate inflammatory mediators. ...CONCLUSIONS: Apremilast was effective in m …
Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial.
Imafuku S, Tada Y, Hippeli L, Banerjee S, Morita A, Ohtsuki M. Imafuku S, et al. J Dermatol. 2023 May;50(5):588-595. doi: 10.1111/1346-8138.16740. Epub 2023 Mar 7. J Dermatol. 2023. PMID: 36882942 Clinical Trial.
The proportion of Japanese patients achieving 75% reduction from baseline in PASI (PASI 75) score was numerically higher with deucravacitinib versus placebo and apremilast at Week 16 (78.1% vs. 11.8% and 23.5%, respectively) and versus apremilast at Week 24 (78.1% v …
The proportion of Japanese patients achieving 75% reduction from baseline in PASI (PASI 75) score was numerically higher with deucravacitini …
Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial.
Merola JF, Parish LC, Guenther L, Lynde C, Lacour JP, Staubach P, Cheng S, Paris M, Picard H, Deignan C, Jardon S, Chen M, Papp KA. Merola JF, et al. J Am Acad Dermatol. 2024 Mar;90(3):485-493. doi: 10.1016/j.jaad.2023.10.020. Epub 2023 Oct 16. J Am Acad Dermatol. 2024. PMID: 37852306 Free article. Clinical Trial.
OBJECTIVE: To assess the efficacy and safety of apremilast 30 mg twice daily in patients with genital psoriasis. METHODS: DISCREET, a phase 3, placebo-controlled trial (NCT03777436), randomized patients with moderate-to-severe genital psoriasis (stratified by affected body …
OBJECTIVE: To assess the efficacy and safety of apremilast 30 mg twice daily in patients with genital psoriasis. METHODS: DISCREET, a …
Preclinical and clinical evidence for suppression of alcohol intake by apremilast.
Grigsby KB, Mangieri RA, Roberts AJ, Lopez MF, Firsick EJ, Townsley KG, Beneze A, Bess J, Eisenstein TK, Meissler JJ, Light JM, Miller J, Quello S, Shadan F, Skinner M, Aziz HC, Metten P, Morrisett RA, Crabbe JC, Roberto M, Becker HC, Mason BJ, Ozburn AR. Grigsby KB, et al. J Clin Invest. 2023 Mar 15;133(6):e159103. doi: 10.1172/JCI159103. J Clin Invest. 2023. PMID: 36656645 Free PMC article. Clinical Trial.
Apremilast also reduced excessive alcohol drinking in models of stress-facilitated drinking and alcohol dependence. ...These results demonstrate that apremilast suppresses excessive alcohol drinking across the spectrum of AUD severity....
Apremilast also reduced excessive alcohol drinking in models of stress-facilitated drinking and alcohol dependence. ...These results …
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behcet's Syndrome.
Mease PJ, Hatemi G, Paris M, Cheng S, Maes P, Zhang W, Shi R, Flower A, Picard H, Stein Gold L. Mease PJ, et al. Am J Clin Dermatol. 2023 Sep;24(5):809-820. doi: 10.1007/s40257-023-00783-7. Epub 2023 Jun 14. Am J Clin Dermatol. 2023. PMID: 37316690 Free PMC article.
OBJECTIVE: The aim of this study was to conduct a pooled analysis of apremilast data from 15 clinical studies with open-label extension phases, focusing on long-term safety. ...RESULTS: Overall, 4183 patients were exposed to apremilast (6788 patient-years). Most TEA …
OBJECTIVE: The aim of this study was to conduct a pooled analysis of apremilast data from 15 clinical studies with open-label extensi …
CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-alpha and MMP-3 production in patients with inflammatory bowel disease.
Gordon JN, Prothero JD, Thornton CA, Pickard KM, Di Sabatino A, Goggin PM, Pender SL, Macdonald TT. Gordon JN, et al. J Crohns Colitis. 2009 Sep;3(3):175-82. doi: 10.1016/j.crohns.2009.03.001. Epub 2009 Apr 10. J Crohns Colitis. 2009. PMID: 21172267
AIM: To investigate the effect of thalidomide, CC-4047 (pomalidomide), CC-5013 (lenalidomide), and CC-10004 (apremilast) on gut LPMC TNFalpha and MMP-3 production in patients with IBD. ...RESULTS: CC-10004 significantly reduced both TNF-alpha pr …
AIM: To investigate the effect of thalidomide, CC-4047 (pomalidomide), CC-5013 (lenalidomide), and CC-10004 (apremilast …
1,193 results